In this article, we will look at the 10 Best Vaccine Stocks to Buy According to Hedge Funds.

What Will Trump’s Tariffs Mean for the Pharma Industry?

On February 24, CNBC reported that President Trump declared that sweeping US tariffs on imports from Mexico and Canada “will go forward” in a statement before the expiry of their month-long delay on their implementation. When asked about the postponed tariffs at a White House press conference, President Trump said:

“The tariffs are going forward on time, on schedule.”

He claimed that foreign nations have been taking advantage of the US in “just about everything,” reiterating his plans to impose “reciprocal tariffs.”

“So the tariffs will go forward, yes, and we’re going to make up a lot of territory,” Trump said.

On February 21, Jared Holz, Mizuho Securities America’s healthcare sector strategist, appeared on CNBC to talk about these tariffs and the ways they could affect the US pharmaceutical sector. Although he was unclear about the exact intention behind these tariffs, he said that he did not consider the pharmaceutical industry to be all that special with respect to other verticals, including technology and industrials, such that President Trump would intend to enlarge its presence in the US.

To him, the tariffs are not just about the generics or branded but are rather more about how the biotech or pharmaceutical industry fits into the grander plans around scaling up domestic manufacturing. Most biotech and pharma companies have a significant presence in the US. However, questions of whether they will hire more people in the US compared to Europe or Asia and whether they will bring back more business to America still stand without answers.

READ ALSO: 10 Best Performing Pharma Stocks So Far in 2025 and 10 Oversold Pharma Stocks to Buy According to Analysts.

Tariffs and On-Shore Capacity in the US

Although Holz was unclear about the answers to such questions, he did say that anything coming out of Europe or China would obviously be fair game. The pharmaceutical companies would say that the Inflation Reduction Act (IRA) as part of the Biden administration is incredibly crippling, and the business that needs to be tied up to make the earnings based on that is very challenging for the sector. Adding Trump’s tariffs to the list would complicate the sector possibly more than others, with the tariffs acting as a “third strike” against the US pharma sector.

Delving deeper into the topic, Holz said that building up manufacturing capacities and facilities from scratch is not as easy as it sounds and requires multiple years to reach a point where companies can produce at a high rate. Therefore, he is unclear about the impact of tariffs on the production capacity and on-shoring of pharma companies.

We recently discussed what Trump’s tariffs could mean for the healthcare industry and looked at another analyst’s perspective on the topic in a recently published article on 12 Most Oversold Healthcare Stocks to Buy Now. Here is an excerpt from the article:

“Since more and more companies in the US are looking towards China for deals regarding the next promising molecule, whether in the obesity or cancer space, the impact of tariffs on this ongoing trend has become a subject of significant discussion in the healthcare industry. On February 7, Carlo Rizzuto, Versant Ventures managing director, appeared on CNBC’s ‘Fast Money’ to discuss the impact of tariffs on healthcare. Rizzuto believed that there are two ways in which tariffs could impact the industry. The first would be products innovated in China and brought over to the US or other markets. To understand how the tariffs would affect such trade processes, the industry would have to see how the tariffs are actually structured in the market.

Secondly and more tangibly, China is a massive center for contract research and manufacturing for the US healthcare industry. Therefore, anything that increases that cost is likely to make the market conditions more challenging. The healthcare industry is already under pressure in terms of investor sentiment, and an increase in cost is not going to help its functioning.”

With these trends in view, let’s look at the 10 best vaccine stocks to buy according to hedge funds.

Our Methodology 

We sifted through stock screeners, online rankings, and ETFs to compile a list of 20 vaccine stocks. We then selected the top 10 most popular stocks among elite hedge funds as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

10 Best Vaccine Stocks to Buy According to Hedge Funds

10. BioNTech SE (NASDAQ:BNTX)

Number of Hedge Fund Holders: 35

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that creates messenger RNA (mRNA) therapeutics and vaccines to address serious diseases such as cancer and infectious diseases. It specializes in developing and manufacturing immunotherapies for patient-specific approaches.

The company reported revenues of €1,244.8 million in fiscal Q3 2024, up from €895.3 million in fiscal Q3 2023. It also grew net profit to €198.1 million from €160.6 million last year, and diluted earnings per share increased to €0.81 ($0.89) from €0.66. This revenue growth was attributed to the approval and successful launch of COVID-19 vaccines for the 2024/2025 season.

BioNTech SE (NASDAQ:BNTX) anticipates full-year 2024 revenues at the lower end of the €2.5-3.1 billion guidance range. It is focusing on advancing its late-stage oncology product candidates and executing them to potential registration. Its strong pipeline and capabilities position the company to execute its vision of becoming a global multiproduct immunotherapy company.

9. GSK plc (NYSE:GSK)

Number of Hedge Fund Holders: 38

Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and pharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer in addition to other drugs.

GSK plc (NYSE:GSK) reported solid financial results for fiscal Q4 2024, reflecting strong growth across key metrics. Its sales grew 8% to over £31 billion in 2024, and core operating profit rose by 13%. Similarly, core earnings per share (EPS) grew by 12%.

This growth was attributed to the company’s Specialty Medicines segment, which rose 19% in sales. Its HIV sales grew by 13% for 2024, and oncology sales nearly doubled to more than £1.4 billion. GSK plc (NYSE:GSK) is continuing to strengthen its pipeline, with 11 positive phase III trials reported in 2024 and five new product approvals anticipated in 2025. These include Blenrep for multiple myeloma and depemokimab for severe asthma.